



# Health Research Authority

## London - Central Research Ethics Committee

3rd Floor, Barlow House  
4 Minshull Street  
Manchester  
M1 3DZ

26 October 2021

Mr G Leonard  
Barts & the London NHS Trust  
R&D Department  
24-26 Walden street  
Whitechapel  
London  
E1 2AN

Dear Mr Leonard,

**Study title:** United Kingdom Adult Idiopathic Thrombocytopenic  
Purpura (ITP) Registry: An Investigation of Disease  
Progression, Treatment Effectiveness, and Co-morbid  
Conditions

**REC reference:** 07/H0718/57

**Amendment number:** Substantial amendment 7

**Amendment date:** 07 September 2021

**IRAS project ID:** 92703

The above amendment was reviewed by the Sub-Committee in correspondence.

### Ethical opinion

The members of the Committee taking part in the review gave a favourable ethical opinion of the amendment on the basis described in the notice of amendment form and supporting documentation.

### Approved documents

The documents reviewed and approved at the meeting were:

<i>Document</i>	<i>Version</i>	<i>Date</i>
Completed Amendment Tool [8. SA 7 Amendment tool LOCKED 20.09.2021]	1.5	07 September 2021
Covering letter on headed paper [6. UKITPR Substantial Amendment 7_Cover Letter]	1	11 August 2021
Other [Protocol Signature page]	4.0	07 September 2021
Other [4. UKITPR Initial Data Collection Sheet v3.0]	3.0	07 September 2021

Other [5. UKITPR Follow-up Information Sheet v3.0]	3.0	07 September 2021
Participant consent form [3. UKITPR Study Informed Consent Agreement v6.0]	6.0	07 September 2021
Participant information sheet (PIS) [2. UKITPR Patient Information Sheet v5.0]	5.0	07 September 2021
Research protocol or project proposal [1. UKITPR Study Protocol v4.0]	4.0	07 September 2021

### Membership of the Committee

The members of the Committee who took part in the review are listed on the attached sheet.

### Working with NHS Care Organisations

Sponsors should ensure that they notify the R&D office for the relevant NHS care organisation of this amendment in line with the terms detailed in the categorisation email issued by the lead nation for the study.

### Amendments related to COVID-19

We will update your research summary for the above study on the research summaries section of our website. During this public health emergency, it is vital that everyone can promptly identify all relevant research related to COVID-19 that is taking place globally. If you have not already done so, please register your study on a public registry as soon as possible and provide the HRA with the registration detail, which will be posted alongside other information relating to your project.

### Statement of compliance

The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK.

### HRA Learning

We are pleased to welcome researchers and research staff to our HRA Learning Events and online learning opportunities– see details at: <https://www.hra.nhs.uk/planning-and-improving-research/learning/>

<b>IRAS Project ID - 92703:</b>	<b>Please quote this number on all correspondence</b>
---------------------------------	---

Yours sincerely



pp

**Dr Andrew Hilson**  
**Chair**

E-mail: [londoncentral.rec@hra.nhs.uk](mailto:londoncentral.rec@hra.nhs.uk)

*Enclosures: List of names and professions of members who took part in the review*

**London - Central Research Ethics Committee**

**Attendance at Sub-Committee of the REC meeting on 24 September 2021**

**Committee Members:**

<i>Name</i>	<i>Profession</i>	<i>Present</i>	<i>Notes</i>
Mr Clive Carsley	Retired Lawyer	Yes	
Dr Andrew Hilson	Retired Consultant in Nuclear Medicine	Yes	(Chaired the meeting)

**Also in attendance:**

<i>Name</i>	<i>Position (or reason for attending)</i>
Mr Matthew Mills	Approvals Administrator